(7) The complexity and intertumoral variability of CRC probably hinders the progress towards developing IGF2-targeted therapeutics and will require a more accurate determination of the molecular profile of IGF2-sensitive tumors. The gene discussed is IGF2; the disease is colorectal carcinoma.